por
Gus Iversen, Editor in Chief | May 26, 2026
Niowave has started construction on a $75 million production facility in Lansing, Michigan, aimed at expanding domestic supply of Actinium-225, a radioisotope used in targeted cancer therapies.
The Lansing-based company said the new site will serve as its second dedicated production facility in the city and is expected to increase manufacturing capacity for Ac-225 and other medical isotopes used in radiopharmaceutical development. The facility is scheduled to become operational in 2028.
Niowave said the project will add about 70 jobs across research and development, engineering and quality assurance. The facility will include superconducting linear accelerators and isotope processing systems designed to support larger-scale production.
Ad Statistics
Times Displayed: 14408
Times Visited: 35 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
Construction will be led by The Christman Company with engineering support from Colliers Engineering & Design.
Ac-225 is an alpha-emitting isotope being studied and used in targeted radiopharmaceutical therapies intended to deliver radiation directly to cancer cells while limiting exposure to surrounding tissue. Interest in the isotope has increased as drugmakers expand development programs in targeted alpha therapies, an area that has attracted investment and partnership activity across the oncology market.
“This expansion reflects our continued commitment to advancing the future of targeted alpha therapy and investing in the Lansing community,” said Mike Zamaira, CEO of Niowave. “Actinium-225 has the potential to transform cancer treatment, and this new facility significantly strengthens our ability to deliver this critical isotope so that therapies can reach patients who need them.”
Michigan Governor Gretchen Whitmer said the project would strengthen the state’s advanced manufacturing and life sciences sectors while supporting isotope production for cancer therapies.
Niowave, founded in 2005, develops superconducting electron linear accelerators and radiochemistry technologies for medical isotope production. The company has recently announced multiple supply agreements tied to Ac-225 production as demand for radiopharmaceutical materials continues to grow.
